HELX
Franklin Genomic Advancements ETF
HELX is an actively managed portfolio of global equity securities of companies relevant to genomic discovery.
Global
EQUITY
Active
MANAGEMENT STYLE
$ 25.8 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | Feb 25, 2020 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| GUARDANT HEALTH, INC. | 8.8 % |
| NATERA INC | 7.0 % |
| KRYSTAL BIOTECH, INC. | 6.5 % |
| LIGAND PHARMACEUTICALS-CL B | 4.4 % |
| UNITED THERAPEUTICS CORP | 3.8 % |
| ADAPTIVE BIOTECHNOLOGIES CORP. | 3.6 % |
| BRIDGEBIO PHARMA, INC. | 3.4 % |
| ELI LILLY & CO | 3.0 % |
| TRAVERE THERAPEUTICS, INC. | 2.8 % |
| VERTEX PHARMACEUTICALS INC | 2.8 % |
Constituent Breakdown
| Number of holdings | 66 |
| Herfindahl-Hirschman Index | 334 |
| Wgt avg mkt cap (mns) | $59,168 |
| Large cap (>$10bn) | 57.2% |
| Mid cap ($2-10bn) | 35.4% |
| Small cap (<$2bn) | 4.0% |
| Developed mkts. | 94.6% |
| Emerging mkts. | 2.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 85.7 % |
 |
BRITAIN | 2.7 % |
 |
GERMANY | 2.4 % |
 |
SOUTH KOREA | 1.8 % |
 |
NETHERLANDS | 1.7 % |
 |
SWITZERLAND | 1.1 % |
 |
IRELAND | 0.8 % |
Historical Performance
Standardized Performance (as of 06/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 10.1% | 44.2% | 12.3% | 9.7% | -5.1% | -- | -- | 8.4% |
| Dividend Yield | 0.0% | 0.6% | 0.2% | 0.1% | 0.1% | -- | -- | 0.1% |
| Total Returns | 10.1% | 44.8% | 12.5% | 9.9% | -4.9% | -- | -- | 8.5% | Ann. Volatility | 24.8% | 21.8% | 23.0% | 21.1% | 24.1% | -- | -- | 27.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.96 | 31% |
| MSCI EAFE | 0.78 | 31% |
| MSCI Emg Mkts | 0.41 | 19% |
Liquidity Measures
| Avg. volume (000) | 4 |
| ADV traded (mns) | $0 |
| Turnover | 0.6% |
| Avg. Bid/Ask (% of price) | 0.57% |
Technical Indicators
| 30d moving avg. (EMA) | $37.94 |
| Relative strength (RSI) | 64 |
| MACD/Signal | 1.56/1.46 |
| Bollinger Bands (Upper/Lower) | $42.82/$34.14 |
| Short interest (% of AUM) | 0.4% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. HELX |
Expenses vs. HELX |
ALTAR Score™ vs. HELX |
|---|---|---|---|---|
| WDNA | WisdomTree BioRevolution Fund | 32.8% | -5 bp | -1.7% |
| GNOM | Global X Genomics & Biotechnology ETF | 28.9% | 0 bp | -1.8% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 28.2% | +18 bp | +3.0% |
| IBB | iShares Biotechnology ETF | 25.4% | -5 bp | +0.4% |
| GNMX | Corgi Genomics & Precision Medicine ETF | 25.4% | -15 bp | -2.7% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 24.9% | -31 bp | +1.2% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 24.0% | +6 bp | +2.6% |
| BBP | Virtus LifeSci Biotech Products ETF | 23.5% | +29 bp | -2.6% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 23.3% | +10 bp | +7.8% |
| BBH | VanEck Biotech ETF | 23.2% | -15 bp | +5.7% |
Risk and Returns: HELX vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/18/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-0.9%
ALTAR SCORE™
2nd
PERCENTILE
AVOID
ETFRC RATING
There are 733 funds in the Global Equity category with an average
ALTAR Score™ of 4.5% and a standard deviation
of 2.6%. HELX's ALTAR Score™ is approximately -2.1 standard
deviations above the category average. This places HELX in the 2nd percentile
among funds in the category.
Sell-Side Consensus
$42.43
PRICE TARGET
+7.3%
UPSIDE